DE60131399T3 - Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung - Google Patents

Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung Download PDF

Info

Publication number
DE60131399T3
DE60131399T3 DE60131399.2T DE60131399T DE60131399T3 DE 60131399 T3 DE60131399 T3 DE 60131399T3 DE 60131399 T DE60131399 T DE 60131399T DE 60131399 T3 DE60131399 T3 DE 60131399T3
Authority
DE
Germany
Prior art keywords
particles
milling
additive material
carrier particles
composite carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60131399.2T
Other languages
German (de)
English (en)
Other versions
DE60131399T2 (de
DE60131399D1 (de
Inventor
John Staniforth
David Morton
Rosella Musa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectura Ltd
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60131399(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0029263A external-priority patent/GB0029263D0/en
Priority claimed from PCT/GB2001/001732 external-priority patent/WO2001078694A2/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Application granted granted Critical
Publication of DE60131399D1 publication Critical patent/DE60131399D1/de
Publication of DE60131399T2 publication Critical patent/DE60131399T2/de
Publication of DE60131399T3 publication Critical patent/DE60131399T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60131399.2T 2000-06-27 2001-06-27 Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung Expired - Lifetime DE60131399T3 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP00113608 2000-06-27
EP00113608 2000-06-27
GB0029263 2000-11-30
GB0029263A GB0029263D0 (en) 2000-11-30 2000-11-30 Method of making particles for use in a pharmaceutical composition
PCT/GB2001/001732 WO2001078694A2 (en) 2000-04-17 2001-04-17 Formulations for use in inhaler devices
WOPCT/GB01/01732 2001-04-17
EP01947612.6A EP1296651B2 (en) 2000-06-27 2001-06-27 Method of making particles for use in a pharmaceutical composition
PCT/GB2001/002860 WO2002000197A1 (en) 2000-06-27 2001-06-27 Method of making particles for use in a pharmaceutical composition

Publications (3)

Publication Number Publication Date
DE60131399D1 DE60131399D1 (de) 2007-12-27
DE60131399T2 DE60131399T2 (de) 2008-04-17
DE60131399T3 true DE60131399T3 (de) 2019-11-14

Family

ID=26071085

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60131399.2T Expired - Lifetime DE60131399T3 (de) 2000-06-27 2001-06-27 Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung

Country Status (13)

Country Link
US (4) US7744855B2 (cg-RX-API-DMAC10.html)
EP (3) EP1913939B1 (cg-RX-API-DMAC10.html)
JP (1) JP5698423B2 (cg-RX-API-DMAC10.html)
KR (1) KR100949539B1 (cg-RX-API-DMAC10.html)
CN (1) CN100551358C (cg-RX-API-DMAC10.html)
AT (1) ATE378039T1 (cg-RX-API-DMAC10.html)
CA (1) CA2413692C (cg-RX-API-DMAC10.html)
DE (1) DE60131399T3 (cg-RX-API-DMAC10.html)
DK (1) DK1913939T3 (cg-RX-API-DMAC10.html)
ES (2) ES2292598T3 (cg-RX-API-DMAC10.html)
IL (2) IL153705A0 (cg-RX-API-DMAC10.html)
PT (2) PT1913939T (cg-RX-API-DMAC10.html)
WO (1) WO2002000197A1 (cg-RX-API-DMAC10.html)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
ES2292598T3 (es) * 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
US8580306B2 (en) * 2000-11-30 2013-11-12 Vectura Limited Particles for use in a pharmaceutical composition
EP2283817B1 (en) * 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0208742D0 (en) * 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
EP1487417A4 (en) 2001-09-17 2010-03-17 Glaxo Group Ltd DRY POWDER DRUG FORMULATIONS
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
CN102688224A (zh) * 2003-04-14 2012-09-26 维克特拉有限公司 用于提高剂量效率的药物组合物和装置
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
WO2005000267A2 (en) * 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
ATE301990T1 (de) 2003-07-25 2005-09-15 Ferring Bv Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
KR20060117909A (ko) * 2003-09-15 2006-11-17 벡투라 리미티드 폐 흡입에 의한 조루 치료용 제약학적 조성물
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
BRPI0606364A2 (pt) 2005-02-10 2010-03-23 Glaxo Group Ltd processo para formar lactose adequada para uso em uma formulaÇço farmacÊutica
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
HUE027537T2 (en) * 2007-09-03 2016-10-28 Nanotherapeutics Inc Granular preparations for the administration of poorly soluble drugs
EP2080508A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
EP2296628B1 (en) 2008-05-22 2014-05-14 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
US9956170B2 (en) 2008-06-26 2018-05-01 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
EP2309984B1 (en) 2008-07-02 2018-04-11 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
WO2010060874A1 (en) 2008-11-25 2010-06-03 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
JP5671001B2 (ja) 2009-03-26 2015-02-18 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
CA2759109A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
KR20160148041A (ko) * 2009-04-24 2016-12-23 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
NZ710384A (en) 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
CA2784207C (en) * 2009-12-14 2018-06-05 Chiesi Farmaceutici S.P.A. Antibiotic microparticles for inhalation
RU2580312C2 (ru) * 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
US9228785B2 (en) 2010-05-04 2016-01-05 Alexander Poltorak Fractal heat transfer device
CA2803418A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
EA024922B1 (ru) 2010-08-03 2016-11-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
EP4008326A1 (en) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
TW201304822A (zh) 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
WO2012073025A1 (en) 2010-11-30 2012-06-07 Vectura Limited Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
KR20140147891A (ko) * 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
ITMI20130572A1 (it) 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
LT3019153T (lt) * 2013-07-11 2018-11-26 Chiesi Farmaceutici S.P.A. Sausų miltelių kompozicija, apimanti anticholinerginį agentą, kortikosteroidą ir beta-adrenerginį agentą, skirta įvedimui inhaliacijos pagalba
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
EP3107548B8 (en) 2014-02-20 2022-07-20 Otitopic Inc. Dry powder formulations for inhalation
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CA2991760C (en) 2014-07-31 2025-05-06 Aspeya US Inc. DRY INHALATION POWDER FORMULATIONS
KR102462058B1 (ko) 2014-10-08 2022-11-01 잠본쏘시에떼퍼아찌오니 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물
ES2971768T3 (es) * 2014-10-08 2024-06-06 Zambon Spa Composición farmacéutica que contiene budesonida y formoterol
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
MA40910A (fr) * 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
EP3485215B1 (en) 2016-07-12 2023-06-07 Alexander Poltorak System and method for maintaining efficiency of a heat sink
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019009335A1 (ja) * 2017-07-04 2019-01-10 村上　正裕 微粒子の製造方法及び微粒子
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
CN113365617B (zh) 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
KR102947433B1 (ko) 2019-04-12 2026-04-06 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
US12269041B2 (en) 2019-09-19 2025-04-08 New Jersey Institute Of Technology Spherical composite powder
KR102330428B1 (ko) 2019-10-14 2021-11-24 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
CN114845708A (zh) 2019-12-19 2022-08-02 乔治亚州大学研究基金会 用于治疗细菌感染和增强抗生素的化合物
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders
CN119278026A (zh) 2022-03-31 2025-01-07 好利安科技有限公司 吸入复合材料和基于载体的制剂组合
AU2023406464A1 (en) 2022-12-02 2025-07-17 Kinaset Therapeutics, Inc. Formulation of a pan-jak inhibitor
WO2024136219A1 (ko) * 2022-12-19 2024-06-27 주식회사 포스테라헬스사이언스 나노 입자를 포함하는 흡입 제형 및 이의 제조 방법

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
US4349542A (en) 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
SE8603812D0 (sv) 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
DE3917617A1 (de) * 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
WO1993025193A1 (fr) * 1992-06-12 1993-12-23 Teijin Limited Preparation pharmaceutique destinee a etre administree par les voies respiratoires
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
AUPM414394A0 (en) * 1994-02-28 1994-03-24 Voxson International Pty. Limited Multi-mode communications system
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
WO1996035516A1 (en) 1995-05-09 1996-11-14 Colorcon Limited Electrostatic coating
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9526495D0 (en) 1995-12-23 1996-02-28 Knoll Ag Therapeutic agents
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5955023A (en) * 1996-11-27 1999-09-21 Callutech, Llc Method of forming composite particle products
DE69732306T2 (de) * 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
GEP20043260B (en) * 1998-03-16 2004-06-25 Nectar Therapeutics Aerosolized Active Agent Delivery and Device for Realization Thereof
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
GB9826783D0 (en) 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
ATE289825T1 (de) 1999-04-21 2005-03-15 1355540 Ontario Inc Methacoline oder histamine formulierungen zur feststellung von asthma
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ES2292598T3 (es) * 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
US8580306B2 (en) * 2000-11-30 2013-11-12 Vectura Limited Particles for use in a pharmaceutical composition
EP2283817B1 (en) * 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US9192915B2 (en) * 2008-05-10 2015-11-24 Brigham Young University Porous composite particulate materials, methods of making and using same, and related apparatuses
ES2440616T3 (es) * 2010-01-27 2014-01-29 Basf Se Agente de recubrimiento que contiene partículas compuestas
US8491908B2 (en) * 2010-06-01 2013-07-23 Canon Kabushiki Kaisha Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle

Also Published As

Publication number Publication date
US20030162835A1 (en) 2003-08-28
EP2266549A3 (en) 2012-01-18
KR100949539B1 (ko) 2010-03-25
ES2632461T3 (es) 2017-09-13
HK1056115A1 (en) 2004-02-06
PT1913939T (pt) 2017-07-19
EP2266549A2 (en) 2010-12-29
DE60131399T2 (de) 2008-04-17
CN100551358C (zh) 2009-10-21
JP5698423B2 (ja) 2015-04-08
US10561613B2 (en) 2020-02-18
US9351928B2 (en) 2016-05-31
EP1296651A1 (en) 2003-04-02
PT1296651E (pt) 2008-02-12
US20180055772A1 (en) 2018-03-01
EP1296651B1 (en) 2007-11-14
US20160243039A1 (en) 2016-08-25
CA2413692A1 (en) 2002-01-03
KR20030051439A (ko) 2003-06-25
EP1296651B2 (en) 2019-07-17
US20100285142A1 (en) 2010-11-11
DK1913939T3 (en) 2017-09-18
WO2002000197A1 (en) 2002-01-03
JP2004501183A (ja) 2004-01-15
ATE378039T1 (de) 2007-11-15
EP2266549B1 (en) 2019-08-07
CA2413692C (en) 2011-10-18
IL153705A (en) 2011-02-28
US7744855B2 (en) 2010-06-29
ES2292598T3 (es) 2008-03-16
CN1438875A (zh) 2003-08-27
IL153705A0 (en) 2003-07-06
DE60131399D1 (de) 2007-12-27
EP1913939A1 (en) 2008-04-23
EP1913939B1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
DE60131399T2 (de) Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung
DE60125344T2 (de) Formulierungen zur verwendung in inhalationsvorrichtungen
DE60132239T2 (de) Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
DE69631119T2 (de) Pulver zur verwendung in trockenpulverinhalatoren
EP1283036B1 (de) Multidosis-Trockenpulverinhalator mit Pulverreservoir
DE60120936T2 (de) Behandlung von atemerkrankungen
DE60128902T2 (de) Formulierungen zur verwendung in inhalationsvorrichtungen
DE69821119T2 (de) Neuartige formulierung zur inhalation mit einer bulkdichte zwischen 0.28 und 0.38 g/ml, mit formoterol
DE69817774T2 (de) Trägerstoff für trockenpulverinhalator, verfahren zu dessen herstellung und diesen enthaltende arzneimittel
AU2001269261B2 (en) Method of making particles for use in a pharmaceutical composition
WO2005018604A2 (de) Neue inhalationspulver enthaltend den cgrp-antagonisten 1-[n2-[3,5-dibrom-n-[[4-(3,4-dihydro-2(1h)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin
HK1056115B (en) Method of making particles for use in a pharmaceutical composition
NZ523246A (en) Composite excipient particles with a mass medium aerodynamic or a volume median diameter of less that 1 micron produced by milling
ZA200210225B (en) Method of making particles for use in a pharmaceutical composition.
HK1152489B (en) Method of making particles for use in a pharmaceutical composition
AU2001269261A1 (en) Method of making particles for use in a pharmaceutical composition
HK1152489A (en) Method of making particles for use in a pharmaceutical composition

Legal Events

Date Code Title Description
8363 Opposition against the patent